Search Results
Results found for "Jonathan F Fay"
- Fluorescence based HTS compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells
.; Drago, F. Current Drug Treatments Targeting Dopamine D3 Receptor. Nature Methods 2011 , 8 (12), 1027–1036. https://doi.org/10.1038/nmeth.1768 . (19) Schueder, F. ; Stein, J.; Stehr, F.; Auer, A.; Sperl, B.; Strauss, M.
- Optimizing HTRF Assays with Fluorescent Ligands: Time-Resolved Fluorescence in GPCR Research
Degorce F, Card A, Soh S, Trinquet E, Knapik GP, Xie B.
- From DNA day to GPCR genomics
B., Panova, O., Hilger, D., Casiraghi, M., He, F., Maul, L., Gmeiner, P., Kobilka, B.
- Decoding GPCR Function: The Role of Mutagenesis in Rational Drug Discovery
Heydenreich, F. M., Marti-Solano, M., Sandhu, M., Kobilka, B. K., Bouvier, M., & Babu, M.
- Advantages of Fluorescent Probes in GPCR Assays
Ciruela F, Jacobson KA, Fernández-Dueñas V.
- GPCR Weekly Whirlwind: Top Receptor Highlights from Sep 30 - Oct 6, 2024!
detecting endogenous GPCR activity in primary cell cultures using ONE-GO biosensors Quantitation of F-actin
- Nanobodies: New Dimensions in GPCR Signaling Research
M., Thian, F. S., Kobilka, T. S., Schnapp, A., Konetzki, I., Sunahara, R. K., Gellman, S.
- Unlocking Cell's Secrets: Spontaneous β-Arrestin-Membrane Preassociation Drives Receptor-Activation
H., Heydenreich, F. M., Kawakami, K., Masureel, M., Maeda, S., Garcia, K.
- Using Live-cell High-Content Screening to Characterize CB2 Ligands: Insights From 16 Synthetic Cannabinoids
References Brogi, S., Corelli, F., Di Marzo, V., Ligresti, A., Mugnaini, C., Pasquini, S., & Tafi, A.
- Overview of adhesion GPCRs self-activation
aGPCR family was performed highlighted a new hydrophobic conserved motif composed of phenylalanine (F)
- Glyco-sulfo hotspots in the chemokine receptor system
C et al. 2013) for O-glycosylation and the sulfinator tool for tyrosine sulfation sites (Monigatti F
- GRK2 in cardiovascular disease and its potential as a therapeutic target
Despite major advances in the field of pharmacological CVD treatments, particularly in the field of heart failure
- The complicated lives of GPCRs in cardiac fibroblasts
October 2022 "The role of different G protein-coupled receptors (GPCRs) in the cardiovascular system is well understood in cardiomyocytes and vascular smooth muscle cells (VSMCs). In the former, stimulation of Gs-coupled receptors leads to increases in contractility, whereas stimulation of Gq-coupled receptors modulates cellular survival and hypertrophic responses. In VSMCs, stimulation of GPCRs also modulates contractile and cell growth phenotypes. Here, we will focus on the relatively less well-studied effects of GPCRs in cardiac fibroblasts, focusing on key signaling events involved in the activation and differentiation of these cells. We also review the hierarchy of signaling events driving the fibrotic response and the communications between fibroblasts and other cells in the heart. We discuss how such events may be distinct depending on where the GPCRs and their associated signaling machinery are localized in these cells with an emphasis on nuclear membrane-localized receptors. Finally, we explore what such connections between the cell surface and nuclear GPCR signaling might mean for cardiac fibrosis." Read more at the source #DrGPCR #GPCR #IndustryNews
- Unlocking the Therapeutic Potential of Previously Undruggable GPCRs
model of neuroinflammation Feasibility validation of Orion analogs in clinical development Cerini, F.
- Ode to GPCRs
Carl F. Cori and Mrs. Cori.
- Adhesion GPCR Consortium Newsletter - May 2024
Bandekar with help from Nathan Zaidman and Abhishek K. Singh
- FDA Approval Is a Strategy Obstacle, Not a Paperwork Problem
But what looks solid internally often fails to signal true readiness from the FDA’s perspective . 👉
- How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology
sense of fun, the kind of scientific joy that makes late-night imaging sessions feel lighter and big failures
- How to Avoid the Most Common Gaps in Your Biotech Pitch
Most biotech pitches don’t fail because the science is weak. They fail because the story is unclear. 👉 A confusing pitch doesn’t just slow down progress.
- How Collaboration Drives GPCR Discoveries
Some worked in one tissue but failed in another. Some detected off-targets.
- The Hidden Burn: How Internal Misalignment Drains Your Biotech’s Runway
Some of the most promising biotech teams aren’t failing; they’re just stuck.
- Decoding Schild Analysis: The Pharmacologist’s Lens on Competitive Antagonism
Yet, any pharmacologist who’s pushed beyond textbook theory knows: biology rarely plays fair. These deviations aren’t failures—they’re clues. In Kenakin's words, “Every slope, every curvature, every failure to fit—those are the whispers of the
- How GPCR Collaboration Built an Innovation Engine
Michelle was part of a cohort that joined as postgrads in shared facilities, pooling reagents, ideas, and failures
- From Pipettes to Platforms: The Evolution of GPCR Research
When technology reduced the cost of failure, scientists could push boundaries faster.
- Predicting GPCR Function: Inside the Carlsson Lab’s Modeling Toolbox
The lab has witnessed both spectacular accuracy and puzzling failures.
- Accelerating GPCR Drug Discovery: What 40 Years of Pharmacology Reveal
A well-behaved molecule in a dish can fail spectacularly in vivo, leaving teams with years of sunk costs
- Transformative GPCR Insights: Unleash New Horizons in Science | Sep 9 - 15, 2024
cardiomyocyte-specific Adhesion G Protein Coupled Receptor G1 (ADGRG1/GPR56) promotes pressure overload-induced heart failure
- Beyond Clearance: The Strategic Power of Irreversible Drug Binding
Good molecules can fail quietly at this stage —not because they’re weak, but because they’re too strong When they’re ignored, they become sources of silent failure : under-penetration, persistent off-target
- How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs
, he lays out the mindset that helped shape products used across biotech and academia—and why play, failure They think too narrowly, focus too early, and equate unexpected results with failure. “You can try, try, try—and fail, fail, fail,” Eric says. But those failures are where new paths emerge, often leading to transformative tools like the IP1 assay Eric Trinquet Built to Fail, Built to Win: Inside the IP1 Assay Origin Story The IP-One assay didn’t
- Understanding Enzyme Inhibition In GPCR Discovery Programs
From failing fast to embracing serendipity, Eric shares the mindset (and messy origin stories) that shaped






















